STOCK TITAN
  1. Home
  2. News
  3. GTHX

G1 Therapeutics, Inc. - GTHX STOCK NEWS

Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.

G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).

In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.

The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.

On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.

For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.

News

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Rhea-AI Summary
G1 Therapeutics, Inc. achieved $46.3 million in net revenue from sales of COSELA for the full year 2023, representing 48% growth over 2022. They provided 2024 net COSELA revenue guidance of $60 to $70 million. The final analysis of the Phase 3 PRESERVE 2 trial evaluating overall survival in metastatic triple negative breast cancer is estimated to occur in the third quarter of 2024. G1 also presented new analyses indicating improved overall survival with subsequent anticancer therapies for patients who previously received trilaciclib. The company's cash runway extends into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.75%
Tags
earnings
-
News

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
G1 Therapeutics, Inc. CEO to participate in Breast & Lung Cancer Panel Discussion at TD Cowen 44th Annual Health Care Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
conferences
-
News

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

Rhea-AI Summary
G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call to provide a financial and corporate update for Q4 and full year 2023 on February 28, 2024. The event will offer insights into the company's performance and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
earnings
News

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

Rhea-AI Summary
G1 Therapeutics, Inc. receives positive recommendation from DMC to continue pivotal Phase 3 trial for trilaciclib in combination with gemcitabine and carboplatin for metastatic triple negative breast cancer, with final analysis expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.13%
Tags
clinical trial
-
News

Life Sciences Ontario Announces Recipients of 2024 LSO Awards

Rhea-AI Summary
Life Sciences Ontario announces the recipients of its 2024 LSO Awards, recognizing outstanding individuals and companies in the life sciences sector. The awardees include Bill Mantel, Dr. Benjamin Rovinski, Dr. Christine Allen, Dr. Durhane Wong-Rieger, and Satellos Bioscience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced positive preliminary overall survival data from the ongoing Phase 2 trial of trilaciclib in combination with the ADC sacituzumab govitecan (SG) in patients with TNBC. COSELA vial volume grew 19% in the fourth quarter of 2023, and the interim OS analysis of the pivotal 1L TNBC trial for trilaciclib is expected in the first quarter of 2024. The company expects its cash runway to extend into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.87%
Tags
none
News

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
conferences
-
News

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced the grant of inducement stock options and restricted stock units to three new employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan. The stock options are exercisable at $3.11 per share, with a ten-year term and vesting over four years. The RSUs have a four-year term, with 25% vesting on the first anniversary of the grant date, and the remainder vesting semi-annually over the remaining three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
none
-
News

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced that data from the randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial indicate that prior use of Trilaciclib with cytotoxic chemotherapy is highly correlated to improved long-term survival with subsequent anticancer therapies. Improved long-term survival was also observed in patients who received prior Trilaciclib with cytotoxic therapy and were unable to receive subsequent anticancer therapy. The data were presented at the 2023 San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
none
News

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced the grant of inducement stock options and restricted stock units to a new employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan. The stock options are exercisable at $2.00 per share, with a ten-year term and vesting over four years, while the RSUs have a four-year term and vesting over the same period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of G1 Therapeutics (GTHX)?

The current stock price of G1 Therapeutics (GTHX) is $7.15 as of September 18, 2024.

What is the market cap of G1 Therapeutics (GTHX)?

The market cap of G1 Therapeutics (GTHX) is approximately 377.2M.

What does G1 Therapeutics, Inc. specialize in?

G1 Therapeutics specializes in developing next-generation oncology therapeutics, focusing on small-molecule therapies to address unmet needs in cancer treatment.

What is COSELA® (trilaciclib)?

COSELA® (trilaciclib) is an FDA-approved drug designed to reduce chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.

What is the PRESERVE 2 trial?

PRESERVE 2 is a global, multi-center, randomized, placebo-controlled Phase 3 trial investigating trilaciclib in patients with metastatic triple-negative breast cancer.

Where is G1 Therapeutics, Inc. located?

G1 Therapeutics is based in Research Triangle Park, North Carolina.

Who are G1 Therapeutics' key partners?

Key partners include Pepper Bio and Jupiter Bioventures, among others, focusing on developing and commercializing therapies like lerociclib.

What recent financial achievements has G1 Therapeutics reported?

For the full year 2023, G1 Therapeutics reported revenues of $82.5 million, a significant increase from $51.3 million in the previous year.

What is lerociclib?

Lerociclib is a differentiated oral CDK4/6 inhibitor being developed for various cancer treatments, including breast cancer and radioprotection.

How can I get more information about G1 Therapeutics?

To learn more, visit their website at www.g1therapeutics.com and follow them on Twitter and LinkedIn.

What types of cancer are G1 Therapeutics’ therapies targeting?

Their therapies target various cancers, including small cell lung cancer, triple-negative breast cancer, and potentially hepatocellular carcinoma.

What are G1 Therapeutics’ future goals?

G1 Therapeutics aims to provide innovative therapeutic advances for people living with cancer through ongoing research, clinical trials, and strategic partnerships.

Stock GTHX logo
G1 Therapeutics, Inc.

Nasdaq:GTHX

GTHX Rankings

#3335 Ranked by Market Cap
N/A Ranked by Dividends

GTHX Stock Data

377.22M
52.76M
10.92%
54.62%
6.46%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
RESEARCH TRIANGLE PARK